Treatment plan — DIS-SCLC

OpenOnco · Treatment Plan

PLAN-AUTO-SCLC-001-V1 · v1 · 2026-04-27

Patient

AUTO-SCLC-001 · Algorithm: ALGO-SCLC-1L

Clinical significance of mutations (ESCAT / OncoKB)

Tumor-board context — the engine does not use these tiers to rank tracks

Biomarker	Variant	ESCAT	OncoKB	Clinical significance	Drugs	Sources
No clinically actionable variants matched in this profile.

Treatment options (2 tracks)

Standard plan

★ DEFAULT

Indication

IND-SCLC-EXTENSIVE-1L

Regimen

Etoposide-platinum + durvalumab (extensive SCLC, 1L)

Drugs + NSZU

Carboplatin (DRUG-CARBOPLATIN) AUC 5-6 IV · Day 1 of 21-day cycle x 4 cycles · IV ✓ NSZU covered
Etoposide (DRUG-ETOPOSIDE) 80-100 mg/m² IV · Days 1, 2, 3 of 21-day cycle x 4 cycles · IV ✓ NSZU covered
Durvalumab (DRUG-DURVALUMAB) 1500 mg IV q3 weeks (induction); 1500 mg q4 weeks (maintenance) · From cycle 1; maintenance until progression · IV ⚠ NSZU — not for this indication

Supportive care

SUP-G-CSF-PRIMARY-PROPHYLAXIS-PROSTATE

Reason

Engine default per algorithm ALGO-SCLC-1L: {'step': 1, 'outcome': False, 'branch': {'result': 'IND-SCLC-EXTENSIVE-1L'}, 'fired_red_flags': [], 'winner_red_flag': None}

Standard plan

Indication

IND-SCLC-LIMITED-1L

Regimen

Etoposide-platinum + concurrent thoracic RT (limited SCLC)

Drugs + NSZU

Cisplatin (DRUG-CISPLATIN) 75 mg/m² IV · Day 1 of 21-day cycle x 4 cycles · IV ✓ NSZU covered
Etoposide (DRUG-ETOPOSIDE) 100 mg/m² IV · Days 1, 2, 3 of 21-day cycle x 4 cycles · IV ✓ NSZU covered

Supportive care

SUP-G-CSF-PRIMARY-PROPHYLAXIS-PROSTATE

Reason

Alternative track presented for HCP consideration

Pre-treatment investigations

Investigations before treatment start · critical / standard / desired · merged across tracks

ID	Name	Priority	Category	Needed for
TEST-CECT-CAP	КТ органів грудної клітки/черевної порожнини/таза з внутрішньовенним контрастуванням	Critical	imaging	all tracks
TEST-BRAIN-MRI-CONTRAST	МРТ головного мозку з контрастом	Standard	—	all tracks

Red flags — PRO / CONTRA aggressive

PRO-AGGRESSIVE

Triggers that push toward the aggressive track

Age ≥75 + ECOG ≥2 OR significant comorbidity — concurrent CRT (limited-stage) poorly tolerated; sequential CRT or single-agent palliative chemo considered.RF-SCLC-FRAILTY-AGE

CONTRA-AGGRESSIVE

Hard contraindications to escalation

Timeline

Treatment timeline — derived from regimen + monitoring schedule

Standard plan

Induction · Etoposide-platinum + durvaluma

21-day cycles × EP × 4; durva maintenance until progression

Standard plan

Induction · Etoposide-platinum + concurren

21-day cycles × 4-6 cycles concurrent with thoracic RT (60 Gy/30 fx once-daily OR 45 Gy/30 fx BID)

MDT brief

Data quality

Unevaluated RedFlags: RF-SCLC-BRAIN-METS-EMERGENCY, RF-SCLC-FRAILTY-AGE, RF-SCLC-HIGH-RISK-BIOLOGY, RF-SCLC-INFECTION-SCREENING, RF-SCLC-ORGAN-DYSFUNCTION, RF-SCLC-PARANEOPLASTIC, RF-SCLC-SVC-SYNDROME

Skill catalog (0/16 activated in this plan)

All registered virtual specialists. ✓ — activated for this case; ○ — not activated (available for other clinical scenarios).

Specialist	skill_id	Version	Last reviewed	Domain
Specialist з клітинної терапії (CAR-T)	`cellular_therapy_specialist`	v0.1.0	2026-04-25	cellular_therapy
Клінічний фармацевт	`clinical_pharmacist`	v0.1.0	2026-04-25	clinical_pharmacy
Гематолог / онкогематолог	`hematologist`	v0.1.0	2026-04-25	hematology_oncology
Гематопатолог (специфічно для лімфом / лейкозів / мієломи)	`hematopathologist`	v0.1.0	2026-04-25	hematopathology
Інфекціоніст / гепатолог	`infectious_disease_hepatology`	v0.1.0	2026-04-25	infectious_diseases
Медичний онколог (хіміотерапевт солідних пухлин)	`medical_oncologist`	v0.1.0	2026-04-25	solid_oncology
Молекулярний генетик / молекулярний онколог	`molecular_geneticist`	v0.1.0	2026-04-25	molecular_oncology
Паліативна допомога	`palliative_care`	v0.1.0	2026-04-25	palliative_care
Патолог (загальний)	`pathologist`	v0.1.0	2026-04-25	pathology
Сімейний лікар / терапевт	`primary_care`	v0.1.0	2026-04-25	primary_care
Психолог / онкопсихолог	`psychologist`	v0.1.0	2026-04-25	psychosocial
Радіотерапевт (променева терапія)	`radiation_oncologist`	v0.1.0	2026-04-25	radiation_oncology
Лікар-радіолог	`radiologist`	v0.1.0	2026-04-25	diagnostic_imaging
Соціальний працівник / кейс-менеджер	`social_worker_case_manager`	v0.1.0	2026-04-25	psychosocial
Хірург-онколог	`surgical_oncologist`	v0.1.0	2026-04-25	surgical_oncology
Specialist з трансплантації (BMT)	`transplant_specialist`	v0.1.0	2026-04-25	cellular_therapy

Sources cited

SRC-ESMO-SCLC-2021: ESMO Clinical Practice Guideline on Small Cell Lung Cancer (2021)
SRC-NCCN-SCLC-2025: NCCN Clinical Practice Guidelines — Small Cell Lung Cancer (2025.v3)

Експериментальні опції (клінічні дослідження)

Третій трек плану — open-enrollment trials з ClinicalTrials.gov. Останнє оновлення: 2026-04-27. Render-time metadata; engine selection не змінюється цим блоком (CHARTER §8.3).

NCT	Name	Phase	Статус	Спонсор	UA
NCT04429087	A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3	PHASE1	RECRUITING	Boehringer Ingelheim	—
NCT06616584	Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)	PHASE2 / PHASE3	RECRUITING	SWOG Cancer Research Network	—
NCT05306652	Exercise in Extended Oncogene Addicted Lung Cancer in Active Treatment	NA	RECRUITING	AUSL Romagna Rimini	—
NCT07016126	D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC	PHASE3	RECRUITING	Guangdong Provincial People's Hospital	—
NCT05014464	ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma	PHASE2	RECRUITING	Hunan Province Tumor Hospital	—
NCT05940532	A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC	PHASE2	RECRUITING	Hunan Cancer Hospital	—
NCT04980716	Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer Patients	PHASE3	RECRUITING	Sun Yat-sen University	—
NCT07467863	Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC	PHASE1 / PHASE2	RECRUITING	Beijing Biotech	—
NCT05276726	A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1	PHASE1 / PHASE2	RECRUITING	Allist Pharmaceuticals, Inc.	—
NCT05609578	Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation	PHASE2	RECRUITING	Mirati Therapeutics Inc.	—

Перевіряти статус набору безпосередньо у дослідницькому центрі. Дані ctgov можуть відставати від поточного статусу UA-сайтів.

Доступність опцій в Україні

Per-track UA registration · НСЗУ · cost · access pathway. Render-time metadata; engine selection не залежить від цих полів (CHARTER §8.3).

Опція	Реєстрація UA	НСЗУ	Cost orientation	Access pathway
Standard plan Etoposide-platinum + durvalumab (extensive SCLC, 1L) (REG-EP-DURVA-SCLC)	✓ зареєстровано	✓ покривається	₴-? — verify pathway	НСЗУ formulary
Standard plan Etoposide-platinum + concurrent thoracic RT (limited SCLC) (REG-EP-CONCURRENT-RT-SCLC-LIMITED)	✓ зареєстровано	✓ покривається	₴-? — verify pathway	НСЗУ formulary
Trial · NCT04429087 A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3 No UA site listed — international referral required	— невідомо	— невідомо	self-pay: ₴0/course	Trial sponsor
Trial · NCT06616584 Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial) No UA site listed — international referral required	— невідомо	— невідомо	self-pay: ₴0/course	Trial sponsor
Trial · NCT05306652 Exercise in Extended Oncogene Addicted Lung Cancer in Active Treatment No UA site listed — international referral required	— невідомо	— невідомо	self-pay: ₴0/course	Trial sponsor
Trial · NCT07016126 D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC No UA site listed — international referral required	— невідомо	— невідомо	self-pay: ₴0/course	Trial sponsor
Trial · NCT05014464 ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma No UA site listed — international referral required	— невідомо	— невідомо	self-pay: ₴0/course	Trial sponsor
Trial · NCT05940532 A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC No UA site listed — international referral required	— невідомо	— невідомо	self-pay: ₴0/course	Trial sponsor
Trial · NCT04980716 Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer Patients No UA site listed — international referral required	— невідомо	— невідомо	self-pay: ₴0/course	Trial sponsor
Trial · NCT07467863 Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC No UA site listed — international referral required	— невідомо	— невідомо	self-pay: ₴0/course	Trial sponsor
Trial · NCT05276726 A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1 No UA site listed — international referral required	— невідомо	— невідомо	self-pay: ₴0/course	Trial sponsor
Trial · NCT05609578 Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation No UA site listed — international referral required	— невідомо	— невідомо	self-pay: ₴0/course	Trial sponsor

Інформація про ціни — orientation. Перевіряти у конкретній аптеці / foundation / трайл-сайті. Status updated: 2026-04-27.

plan_id: PLAN-AUTO-SCLC-001-V1 | version: 1 | generated: 2026-04-27T10:14:01.655465+00:00

Per FDA non-device CDS positioning (CHARTER §15): Outpatient oncology treatment planning to support tumor-board discussion. Not a medical device; not for autonomous clinical decision-making.

Per FDA non-device CDS positioning (CHARTER §15): Both treatment options below are presented for review. The engine's selection of a 'recommended' default does not constitute a clinical decision. Final treatment selection requires HCP judgment incorporating information not available to the system.

This document is an informational resource supporting tumor-board discussion (per CHARTER §11). It is not a system that makes clinical decisions. Every recommendation must be verified by the treating physician.